#151492

Anti-MHCII [BU20]

Cat. #151492

Anti-MHCII [BU20]

Cat. #: 151492

Unit size: 100 ug

Availability: 3-4 weeks

Target: Major Histocompatibility Complex (MHC II)

Class: Monoclonal

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Margaret Goodall ; D.L. Hardie ; Roy Jefferis ; Ian MacLennen

Institute: University of Birmingham

Tool Details
Target Details
Handling

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-MHCII [BU20]
  • Research fields: Immunology
  • Clone: BU20
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Host: Mouse
  • Description: Human Leukocyte Antigens are highly polymorphic proteins that are involved in the presentation of antigens to the T-cell receptor. There are two classes of HLA antigens, class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D).
  • Isotype: IgG1
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Major Histocompatibility Complex (MHC II)
  • Target background: Human Leukocyte Antigens are highly polymorphic proteins that are involved in the presentation of antigens to the T-cell receptor. There are two classes of HLA antigens, class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D).

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1mg/ml
  • Unit size: 100 ug
  • Storage buffer: RPMI 1640 + 10% FCS
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.